TICKERNERD
Menu
DERMDERMHealthcare · Drug Manufacturers - Specialty & Generic

DERM Stock Forecast: Journey Medical Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$7.76
+3.54% on the day

The 4 Wall Street analysts covering Journey Medical Corp. hold a median 12-month price target of $14 — +74.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 67 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$218.7M
Ticker Nerd rank
67 / 100
Median analyst target
$14
Analysts covering
4
Total return, dividends reinvested
1W
+15.4%
1M
+6.1%
YTD
+0.6%
1Y
+9.5%
From 52W high
−16.3%
From 52W low
+76.7%
$4.39
$9.26
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DERM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Journey Medical Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
67 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
96
Value
89
Quality
79
Volatility
76
Size
68
Momentum
52
Revisions
38
Issuance
28
Accruals
18

Growth (96): Sales and profits are climbing, and climbing faster than before.

Accruals (18): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DERM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DERM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4.00$6.00$8.00$10.00$12.00$14.00$16.00Oct 25Jan 26Apr 26Jul 26DERMHigh $15Median $14Low $13

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $13Median $14High $15

The green dot is the last close — the median target sits +74.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
13 Aug 2026B. Riley SecuritiesReiteratesBuy$12 → $15
26 Mar 2026HC Wainwright & Co.ReiteratesBuy$13
26 Mar 2026HC Wainwright & Co.ReiteratesBuy—
25 Aug 2025HC Wainwright & Co.InitiatesBuy—
13 Aug 2025Lake StreetMaintainsBuy—
30 July 2025B. Riley SecuritiesMaintainsBuy—
6 Sept 2024Lake StreetInitiatesBuy$9.00
22 Aug 2024Rodman & RenshawInitiatesBuy$9.00
28 June 2024Roth MKMReinstatesBuy$11
16 Feb 2024Alliance Global PartnersInitiatesBuy—
7 Sept 2023B. Riley SecuritiesReiteratesBuy—
12 July 2023B. Riley SecuritiesMaintainsBuy—
23 May 2023B. Riley SecuritiesMaintainsBuy—
30 Mar 2023B. Riley SecuritiesReiteratesBuy—
25 Feb 2022Cantor FitzgeraldInitiatesOverweight—
16 Dec 2021Roth CapitalInitiatesBuy—
7 Dec 2021B. Riley SecuritiesInitiatesBuy—
6 June 2019MizuhoUpgradeBuy$17 → $14
6 Mar 2018MizuhoDowngradeNeutral$39 → $9.00
16 Mar 2016CitigroupMaintainsBuy$42 → $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DERM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

DERM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−153.8%
Analysts raising
0
Analysts cutting
0
Fundamentals

Journey Medical Corp. (DERM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
39.1×

Cheaper than 20% of US stocks

Price / sales
3.2×

Cheaper than 40% of US stocks

Price / book
6.7×

Cheaper than 16% of US stocks

EV / EBITDA
179.8×

Cheaper than 1% of US stocks

Growth & margins
Revenue growth (YoY)
23.3%

Higher than 73% of US stocks

Earnings growth (YoY)
21.5%

Higher than 60% of US stocks

Gross margin
61.0%

Higher than 74% of US stocks

Operating margin
2.5%

Higher than 49% of US stocks

Net margin
−9.0%

Higher than 21% of US stocks

Returns & dividend
Return on equity
−23.8%

Higher than 30% of US stocks

Return on assets
−2.1%

Higher than 37% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

DERM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
DERMJourney Medical Corp.$218.7M
67
CRDLCardiol Therapeutics, Inc.$217.4M
62
SIGASIGA Technologies, Inc.$217.8M
42
ORGOOrganogenesis Holdings, Inc.$228.4M
52
AKBAAkebia Therapeutics, Inc.$242.9M
75
OGIOrganigram Global, Inc.$177.3M
40
ACBAurora Cannabis, Inc.$255.2M
34

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Journey Medical Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DERM news & analysis

Journey Medical: Q2 Report Confirms Thesis On Track As Emrosi Launch Gains Traction

Seeking Alpha · 19 Aug 2026positive

Journey Medical's Q2 report showed Emrosi prescription growth rebounding from Q1 lows, with revenues up 23% to $18.5M and positive EBITDA. Prescribers rose over 40% quarter-over-quarter, formulary coverage improved from 34% to 38%, and cost discipline was evident as SG&A declined.

Why it matters — The report confirms DERM's thesis is on track as the Emrosi franchise gains traction through rising prescribers, improved formulary coverage, and disciplined costs.

Journey Medical Corporation (DERM) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

Journey Medical Corporation held its Q2 2026 earnings call, with the transcript published on Seeking Alpha.

Why it matters — DERM watchers would care because earnings calls provide direct insight into the company's financial performance and strategic outlook.

Here's What Key Metrics Tell Us About Journey Medical (DERM) Q2 Earnings

Zacks Investment Research · 12 Aug 2026neutral

A Zacks Research report discusses Journey Medical Corp.'s (DERM) headline results for the quarter ended June 2026, suggesting it may be useful to compare some of the company's key metrics against Wall Street estimates and year-ago actuals.

Why it matters — DERM watchers would care because comparing key quarterly metrics to analyst estimates and prior-year results offers insight into how the company performed in the June 2026 quarter.

Journey Medical Q2 Earnings Call Highlights

MarketBeat · 12 Aug 2026positive

Journey Medical reported higher second-quarter revenue and a sharply narrower net loss, driven by continued growth in sales of its rosacea treatment EMROSI. The growth was supported by rising prescription volume, broader prescriber adoption, and improving payer reimbursement.

Why it matters — The improving revenue and narrower losses tied to EMROSI growth signal stronger commercial momentum for the company's lead product.

Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

GlobeNewsWire · 12 Aug 2026neutral

Journey Medical Corporation announced its second quarter 2026 financial results and highlighted recent corporate developments. The company provided an update on its financial performance and business activities for the quarter.

Why it matters — A Journey Medical (DERM) watcher would care because the quarterly financial results and corporate highlights offer insight into the company's recent performance and strategic progress.

FAQ

Frequently asked questions about DERM stock

What is the DERM stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Journey Medical Corp. have a median 12-month price target of $14, with estimates ranging from $13 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DERM stock a buy right now?

Of the 4 analysts covering Journey Medical Corp., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Journey Medical Corp. 67 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DERM?

As at 22 Aug 2026, Journey Medical Corp. ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (96 of 100).

Will DERM stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +74.1% from the last close, and Ticker Nerd's factor model ranks Journey Medical Corp. 67 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DERM stock forecast for 2030?

No analyst covering Journey Medical Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DERM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $15 over the next 12 months.

How has DERM stock performed over the past year?

Journey Medical Corp. returned +9.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Journey Medical Corp. do?

Journey Medical Corp is an esteemed biopharmaceutical company focused on the dermatological sector. Its primary function is to develop and commercialize innovative pharmaceutical products that address the unmet medical needs in dermatology.

What is the latest news on DERM?

The most recent item we track (Seeking Alpha, 19 Aug 2026): "Journey Medical: Q2 Report Confirms Thesis On Track As Emrosi Launch Gains Traction". Journey Medical's Q2 report showed Emrosi prescription growth rebounding from Q1 lows, with revenues up 23% to $18.5M and positive EBITDA. Prescribers rose over 40% quarter-over-quarter, formulary coverage improved from 34% to 38%, and cost discipline was evident as SG&A declined.

Company

About Journey Medical Corp.

Journey Medical Corp is an esteemed biopharmaceutical company focused on the dermatological sector. Its primary function is to develop and commercialize innovative pharmaceutical products that address the unmet medical needs in dermatology. Journey Medical Corp's portfolio includes a wide range of dermatological products designed to treat various conditions, including acne, rosacea, and other skin disorders. The company's emphasis on dermatology allows it to significantly impact the healthcare industry by providing critical treatments that enhance patient care and outcomes. As a player in the biopharmaceutical market, Journey Medical Corp contributes to advancing medical research and development, particularly in skin care solutions. This focus not only enhances its importance in the healthcare sector but also emphasizes the growing need for specialized therapies in dermatology, underscoring its role in improving the quality of life for patients suffering from chronic skin conditions.

CEO Mr. Claude Maraoui · 58 employees · United States · https://journeymedicalcorp.com